AVXL – anavex life sciences corp. (US:AMEX)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

AVXL

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/24

10:30 am

avxl

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Low Report

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Report

12/22

08:02 am

avxl

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Low Report

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Report

12/18

07:30 am

avxl

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Low Report

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Report

12/17

10:20 am

avxl

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Low Report

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Report

12/15

08:06 am

avxl

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.

Medium Report

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.

Report

12/12

05:32 pm

avxl

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]

Medium Report

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]

Report

12/12

04:05 pm

avxl

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

Low Report

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

Report

12/11

10:00 am

avxl

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Neutral Report

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Report

12/10

09:50 am

avxl

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Medium Report

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Report

12/3

07:39 pm

avxl

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Medium Report

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Report

12/2

10:00 pm

avxl

Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's [Seeking Alpha]

High Report

Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's [Seeking Alpha]

Report

12/2

11:47 am

avxl

Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) [Yahoo! Finance]

Low Report

Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) [Yahoo! Finance]

Report

11/28

07:02 am

avxl

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Low Report

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

11/26

02:01 pm

avxl

Anavex Life Sciences (NASDAQ:AVXL) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Low Report

Anavex Life Sciences (NASDAQ:AVXL) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Report

11/26

12:56 pm

avxl

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.

Medium Report

Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.

Report

11/26

07:53 am

avxl

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference [Yahoo! Finance]

Medium Report

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference [Yahoo! Finance]

Report

11/26

07:30 am

avxl

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

High Report

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Report

11/25

04:20 pm

avxl

Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]

High Report

Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]

Report

11/25

07:58 am

avxl

Anavex Life Sciences: Fiscal Q4 Earnings Snapshot [Yahoo! Finance]

Low Report

Anavex Life Sciences: Fiscal Q4 Earnings Snapshot [Yahoo! Finance]

Report

11/25

07:30 am

avxl

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

High Report

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Report

11/19

10:01 am

avxl

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Low Report

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Report

11/19

08:07 am

avxl

Anavex Life Sciences (NASDAQ:AVXL) had its price target lowered by analysts at HC Wainwright from $42.00 to $20.00. They now have a "buy" rating on the stock.

Low Report

Anavex Life Sciences (NASDAQ:AVXL) had its price target lowered by analysts at HC Wainwright from $42.00 to $20.00. They now have a "buy" rating on the stock.

Report

11/19

07:30 am

avxl

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Low Report

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Report

11/18

07:56 pm

avxl

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Medium Report

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Report

11/18

07:30 am

avxl

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Low Report

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.